Literature DB >> 31054147

Screening for hereditary cancers in patients with endometrial cancer reveals a high frequency of germline mutations in cancer predisposition genes.

Wenjuan Tian1,2, Rui Bi2,3, Yulan Ren1,2, Hongsheng He4, Shanfu Shi4, Boer Shan1,2, Wentao Yang2,3, Qing Wang5,6, Huaying Wang1,2.   

Abstract

As inherited genetic alterations are important etiological factors causing endometrial cancer (EC), our study aimed to outline the ethnic-related prevalence and the associated clinical and biological characteristics of germline mutations in cancer predisposition genes in Chinese EC patients. One hundred ninety-eight Chinese EC patients were screened for germline mutations in a panel of cancer susceptibility genes using next-generation sequencing combined with multiplex ligation-dependent probe amplification. First, we found that among patients under 50 years of age, 26% (18/69) carried germline genetic mutations, all involving mismatch repair (MMR) genes except for one mutation affecting BRCA1. Second, when we focused on Lynch syndrome (LS) with additional selected patients, 45 were identified to carry pathogenic mutations in MMR genes, with a higher frequency found in MSH2 and MSH6. We found that age at onset, personal and familial history together with immunohistochemical assay results were the most useful criteria for the diagnosis of LS although limitations in routine practice and the sensitivity and specificity of each parameter should be taken into account. One pathogenic mutation in the PALB2 gene was detected in a patient with no breast cancer in her family. Interestingly, we identified a family carrying pathogenic variant in both PMS2 and BRCA1 genes with distinct clinical phenotypes. Multigene panel testing should be recommended to patients based on their clinical information and tumor phenotype. Our study also showed the genetic complexity in EC, which requires further investigations.
© 2019 UICC.

Entities:  

Keywords:  Lynch syndrome; endometrial cancer; hereditary cancer; mismatch repair gene; next-generation sequencing

Mesh:

Substances:

Year:  2019        PMID: 31054147     DOI: 10.1002/ijc.32389

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Epigenetic Dysregulation at the Crossroad of Women's Cancer.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Pranela Rameshwar; M Radhakrishna Pillai
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

2.  Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.

Authors:  Maria Teresa Vietri; Giovanna D'Elia; Gemma Caliendo; Amelia Casamassimi; Alessandro Federico; Luana Passariello; Michele Cioffi; Anna Maria Molinari
Journal:  Med Oncol       Date:  2021-01-23       Impact factor: 3.064

Review 3.  Overview on population screening for carriers with germline mutations in mismatch repair (MMR) genes in China.

Authors:  Min Zhang; Tianhui Chen
Journal:  Hered Cancer Clin Pract       Date:  2021-05-01       Impact factor: 2.164

4.  Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer.

Authors:  Edward D Esplin; Sarah M Nielsen; Sara L Bristow; Judy E Garber; Heather Hampel; Huma Q Rana; N Jewel Samadder; Neal D Shore; Robert L Nussbaum
Journal:  JCO Precis Oncol       Date:  2022-09

5.  Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.

Authors:  Chris Stinton; Mary Jordan; Hannah Fraser; Peter Auguste; Rachel Court; Lena Al-Khudairy; Jason Madan; Dimitris Grammatopoulos; Sian Taylor-Phillips
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

6.  The pan-cancer landscape of prognostic germline variants in 10,582 patients.

Authors:  Ajay Chatrath; Roza Przanowska; Shashi Kiran; Zhangli Su; Shekhar Saha; Briana Wilson; Takaaki Tsunematsu; Ji-Hye Ahn; Kyung Yong Lee; Teressa Paulsen; Ewelina Sobierajska; Manjari Kiran; Xiwei Tang; Tianxi Li; Pankaj Kumar; Aakrosh Ratan; Anindya Dutta
Journal:  Genome Med       Date:  2020-02-17       Impact factor: 11.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.